Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Public ClinicalTrials.gov record NCT07680790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy
Study identification
- NCT ID
- NCT07680790
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 850 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2026
- Primary completion
- Dec 29, 2031
- Completion
- Dec 29, 2031
- Last update posted
- Aug 23, 2026
2026 – 2031
United States locations
- U.S. sites
- 36
- U.S. states
- 23
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0212 | Beverly Hills | California | 90211 | — |
| Local Institution - 0504 | Fullerton | California | 92835 | — |
| Local Institution - 0357 | La Jolla | California | 92093 | — |
| Local Institution - 0520 | Pueblo | Colorado | 81003 | — |
| Local Institution - 0527 | Fort Myers | Florida | 33901 | — |
| Local Institution - 0366 | Orlando | Florida | 32806 | — |
| Local Institution - 0519 | Palm Bay | Florida | 32901 | — |
| Local Institution - 0526 | St. Petersburg | Florida | 33701 | — |
| Local Institution - 0524 | West Palm Beach | Florida | 33401 | — |
| Local Institution - 0210 | Honolulu | Hawaii | 96813 | — |
| Local Institution - 0207 | Ottawa | Illinois | 61350 | — |
| Local Institution - 0503 | Baltimore | Maryland | 21202 | — |
| Local Institution - 0523 | Silver Spring | Maryland | 20904 | — |
| Local Institution - 0521 | Edina | Minnesota | 55435 | — |
| Local Institution - 0364 | Saint Paul | Minnesota | 55102 | — |
| Local Institution - 0403 | St Louis | Missouri | 63110 | — |
| Local Institution - 0402 | Omaha | Nebraska | 68198 | — |
| Local Institution - 0290 | Lebanon | New Hampshire | 03756 | — |
| Local Institution - 0183 | New Brunswick | New Jersey | 08901 | — |
| Local Institution - 0153 | New York | New York | 10021 | — |
| Local Institution - 0157 | The Bronx | New York | 10461 | — |
| Local Institution - 0385 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0438 | Sandusky | Ohio | 44870 | — |
| Local Institution - 0404 | Portland | Oregon | 97213 | — |
| Local Institution - 0487 | Easton | Pennsylvania | 18045 | — |
| Local Institution - 0200 | Sioux Falls | South Dakota | 57105 | — |
| Local Institution - 0199 | Memphis | Tennessee | 38120 | — |
| Local Institution - 0522 | Beaumont | Texas | 77702 | — |
| Local Institution - 0525 | Dallas | Texas | 75246 | — |
| Local Institution - 0529 | San Antonio | Texas | 78217 | — |
| Local Institution - 0411 | Salt Lake City | Utah | 84112 | — |
| Local Institution - 0165 | Fairfax | Virginia | 22031 | — |
| Local Institution - 0530 | Fairfax | Virginia | 22031 | — |
| Local Institution - 0528 | Winchester | Virginia | 22601 | — |
| Local Institution - 0283 | Seattle | Washington | 98104 | — |
| Local Institution - 0502 | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 172 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07680790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2026 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07680790 live on ClinicalTrials.gov.